Stocks
USANA Health Sciences Financial Statements (USNA) |
||||||||||
| USANA Health Sciencessmart-lab.ru | % | 2021 | 2022 | 2022 | 2023 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 01.03.2022 | 31.12.2022 | 28.02.2023 | 31.12.2023 | 27.02.2024 | 05.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 1 186 | 998.6 | 998.6 | 921.0 | 921.0 | 826.2 | |||
| Operating Income, bln rub | 170.2 | 107.6 | 107.6 | 93.1 | 93.1 | 66.9 | ||||
| EBITDA, bln rub | ? | 192.9 | 108.6 | 130.2 | 93.1 | 113.5 | 84.3 | |||
| Net profit, bln rub | ? | 116.5 | 69.4 | 69.4 | 63.8 | 63.8 | 42.1 | |||
| OCF, bln rub | ? | 121.2 | 103.9 | 70.6 | 37.5 | |||||
| CAPEX, bln rub | ? | 12.8 | 10.4 | 14.5 | 5.07 | |||||
| FCF, bln rub | ? | 108.5 | 93.5 | 56.1 | 32.5 | |||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | ||||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 798.4 | 697.1 | 697.1 | 651.2 | 651.2 | 592.7 | ||||
| Cost of production, bln rub | 217.9 | 193.9 | 193.9 | 176.7 | 176.7 | 163.0 | ||||
| R&D, bln rub | 11.1 | 0.000 | 11.6 | 0.000 | 11.4 | 0.000 | ||||
| Interest expenses, bln rub | 0.057 | 0.000 | 0.192 | 0.000 | 0.262 | 0.200 | ||||
| Assets, bln rub | 577.7 | 596.5 | 596.5 | 632.8 | 632.8 | 612.5 | ||||
| Net Assets, bln rub | ? | 395.1 | 434.5 | 434.5 | 497.2 | 497.2 | 533.1 | |||
| Debt, bln rub | 7.08 | 0.000 | 6.89 | 0.786 | 13.2 | 0.000 | ||||
| Cash, bln rub | 239.8 | 288.4 | 288.4 | 330.4 | 330.4 | 364.9 | ||||
| Net debt, bln rub | -232.8 | -288.4 | -281.5 | -329.6 | -317.2 | -364.9 | ||||
| Ordinary share price, rub | 101.2 | 53.2 | 53.2 | 53.6 | 53.6 | 45.1 | ||||
| Number of ordinary shares, mln | 20.1 | 19.2 | 19.3 | 19.3 | 19.3 | 19.1 | ||||
| Market cap, bln rub | 2 039 | 1 022 | 1 024 | 1 037 | 1 032 | 860 | ||||
| EV, bln rub | ? | 1 806 | 733 | 743 | 707 | 715 | 495 | |||
| Book value, bln rub | 347 | 385 | 385 | 480 | 450 | 487 | ||||
| EPS, rub | ? | 5.78 | 3.61 | 3.60 | 3.30 | 3.31 | 2.21 | |||
| FCF/share, rub | 5.38 | 0.00 | 4.86 | 0.00 | 2.92 | 1.70 | ||||
| BV/share, rub | 17.2 | 20.0 | 20.0 | 24.8 | 23.4 | 25.5 | ||||
| EBITDA margin, % | ? | 16.3% | 10.9% | 13.0% | 10.1% | 12.3% | 10.2% | |||
| Net margin, % | ? | 9.82% | 6.94% | 6.94% | 6.93% | 6.93% | 5.09% | |||
| FCF yield, % | ? | 5.32% | 0.00% | 9.13% | 0.00% | 5.44% | 3.78% | |||
| ROE, % | ? | 29.5% | 16.0% | 16.0% | 12.8% | 12.8% | 7.89% | |||
| ROA, % | ? | 20.2% | 11.6% | 11.6% | 10.1% | 10.1% | 6.87% | |||
| P/E | ? | 17.5 | 14.7 | 14.8 | 16.3 | 16.2 | 20.4 | |||
| P/FCF | 18.8 | 11.0 | 18.4 | 26.5 | ||||||
| P/S | ? | 1.72 | 1.02 | 1.03 | 1.13 | 1.12 | 1.04 | |||
| P/BV | ? | 5.88 | 2.66 | 2.66 | 2.16 | 2.29 | 1.77 | |||
| EV/EBITDA | ? | 9.36 | 6.75 | 5.70 | 7.60 | 6.30 | 5.87 | |||
| Debt/EBITDA | -1.21 | -2.66 | -2.16 | -3.54 | -2.80 | -4.33 | ||||
| R&D/CAPEX, % | 87.1% | 111.2% | 79.0% | 0 | ||||||
| CAPEX/Revenue, % | 1.08% | 0.00% | 1.04% | 0.00% | 1.57% | 0.61% | ||||
| USANA Health Sciences shareholders | ||||||||||
